Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Rocakinogene Sifuplasmid
Hepatocellular Carcinoma
National Cancer Institute (NCI)
P1
C
(37)
Autologous Hucd19 Car T Cells
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
P1/2
C
(37)
Dordaviprone
Colorectal Carcinoma
National Cancer Institute (NCI)
P1
C
(36)
Grt-R904
Breast Cancer
National Cancer Institute (NCI)
P1
C
(36)
Grt-R904
Ovarian Cancer
National Cancer Institute (NCI)
P1
C
(36)
Autologous Hucd19 Car T Cells
B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
P1/2
C
(36)
Revumenib
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
National Cancer Institute (NCI)
P1
C
(35)
Cabozantinib
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)
P1
C
(34)
Egfr/B7H3 Car-T
Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P1
C
(34)
Hepatitis A Vaccine
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
C
(33)
Cabozantinib
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)
P1
C
(33)
Magrolimab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
P1
C
(33)
Magrolimab
Follicular Lymphoma
National Cancer Institute (NCI)
P1
C
(33)
Magrolimab
Mantle Cell Lymphoma
National Cancer Institute (NCI)
P1
C
(33)
Magrolimab
Marginal Zone Lymphoma
National Cancer Institute (NCI)
P1
C
(33)
Vismodegib
Hepatocellular Carcinoma
National Cancer Institute (NCI)
P2
C
(32)
Vismodegib
Melanoma
National Cancer Institute (NCI)
P2
C
(32)
Vismodegib
Skin Carcinoma
National Cancer Institute (NCI)
P2
C
(32)
cd22 car-transduced t cells
Precursor B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P1
C
(32)
Vismodegib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
D
(31)
Vismodegib
Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
D
(31)
Vismodegib
Glioma
National Cancer Institute (NCI)
P2
D
(31)
Vismodegib
Lung Carcinoma
National Cancer Institute (NCI)
P2
D
(31)
Vismodegib
Thyroid Gland Carcinoma
National Cancer Institute (NCI)
P2
D
(31)
Sasanlimab
Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)
P1/2
D
(31)
Showing 3201 to 3225 of 3,272 assets
Previous
Page 129 of 131
Next